Protease-Activated Receptor-4
Cat.No:CLP0513 Solarbio
CAS:245443-52-1
Purity:≥95%
Appearance:Lyophilized powder
Storage:Store at -20℃,2 years.(Avoid freeze/thaw cycles)
Qty:
Size:
{{cart_num}}
My CartCAS:245443-52-1
Purity:≥95%
Appearance:Lyophilized powder
Storage:Store at -20℃,2 years.(Avoid freeze/thaw cycles)
Qty:
Size:
Product Type | Peptides |
CAS | 245443-52-1 |
Sequence(1LC) | GYPGKF-NH2 |
Sequence(3LC) | Gly-Tyr-Pro-Gly-Lys-Phe-NH2 |
Molecular Formula | C33H46N8O7 |
Molecular Weight | 666.78 |
Purity | ≥95% |
Appearance | Lyophilized powder |
Solubility | H2O:50 mg/mL; *Ultrasonic solubilization; |
Salt Form | Trifluoroacetate salt |
Source | Synthetic |
Storage | Store at -20℃,2 years.(Avoid freeze/thaw cycles) |
Category/Label | Protein Kinase Related Peptides |
Background | Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4). |
In Vitro | GYPGKF-NH2 significantly reduces the agonistic potency of AYPGKF-NH2 by 25-fold. GYPGKF-NH2 (500 μM) does not cause contraction or relaxation of the guinea pig IAS strips. |
Reference | [1] Fang, J. et al. Blood 106, 2671(2005); [2] Mulè, F. et al. Gut. 53, 229 (2004); [3] Sekiguchi, F. et al. Drug Design Rev. 1, 287 (2004); [4] Faruqi, T. et al. J. Biol. Chem. 275, 19728 (2000); [5] Greenberg, D. Biochem. 42, 2702 (2003); [6] Henriksen, R. and V. Hanks, Arterioscler. Thromb. Vasc. Biol. 22, 861 (2002); [7] Gui, Y. et al. Am. J. Physiol. Renal. Physiol. 285, 95 (2003). |
Unit | Bottle |
Specification | 1mg 5mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.